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Abstract 
Background 
Most economic evaluations of smoking cessation interventions have used cohort state-transition 
models. Discrete event simulations (DES) have been proposed as a superior approach. 
Objective 
We developed a state-transition model, and a DES using the Discretely Integrated Condition Event 
framework and compared the cost-effectiveness results. We performed scenario analysis using the 
DES to explore the impact of alternative assumptions. 
Methods 
The models estimated the costs and quality-adjusted life years (QALYs) for the intervention and 
comparator from the perspective of the UK National Health Service and Personal Social Services over 
a lifetime horizon. The models considered five comorbidities: chronic obstructive pulmonary disease, 
myocardial infarction, coronary heart disease, stroke and lung cancer. The state-transition model used 
prevalence data and the DES used incidence. The costs and utility inputs were the same between two 
models, and consistent with those used in previous analyses for the National Institute for Health and 
Care Excellence.    
Results 
In the state-transition model, the intervention produced an additional 0.16 QALYs at a cost of £540, 
leading to an incremental cost-effectiveness ratio (ICER) of £3,438. The comparable DES scenario 
produced an ICER of £5,577. The ICER for the DES increased to £18,354 when long-term relapse 
was included. 
Conclusions 
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The model structures themselves did not influence smoking cessation cost-effectiveness results, but 
long-term assumptions did. When there is variation in long-term predictions between interventions, 
economic models need a structure that can reflect this. 
 
Key points for decision makers 
x Two economic models with different structures produced similar results for the cost-
effectiveness of a smoking cessation intervention 
x Including long-term relapse in one of the economic models dramatically changed the results 
x Before building economic models, developers should consider the full treatment pathway of 
the decision problem 
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1. Introduction 
Economic models may use different structures, and there is much discussion and guidance in the 
literature on how to choose the model structure[1-4]. The choice of model structure is viewed as 
important in any disease or health area, including in smoking cessation.  Discrete event simulation 
(DES) models are noted to offer advantages over state-transition models in terms of incorporating 
history, avoiding limitations of discrete time intervals and facilitating a flexible framework[5]. 
Commonly cited disadvantages of DESs include the need for additional data, complexity of 
programming, the need for specialist software, and long run-times. 
The Discretely Integrated Condition Event (DICE) simulation framework has been developed to allow 
modellers to build flexible models in Microsoft Excel[6]. DICE can operate at the individual level or 
cohort level, and be driven by states (for state-transition modelling) or by events (for DESs). For 
modellers developing DESs, DICE removes the need to use specialist software and simplifies the 
coding process. The use of DICE has previously been explored in DES modelling, where it was noted 
that the DICE produced results almost identical to the original ones[7]. 
In 2013, Getsios et al reported that models which consider only one smoking cessation attempt lead to 
biased estimates of cost-effectiveness, and suggest that DES provides a framework for modelling 
multiple quit attempts in smoking cessation[8]. The majority of economic models in smoking 
cessation to date have been cohort-level state-transition (Markov) or decision tree models[9, 10]. 
Indeed, the economic models used in the smoking cessation guidelines produced by the National 
Institute for Health and Care Excellence (NICE) are all cohort-level models[11-17]. There therefore 
remains a question as to whether DES models would generate the same results as state-transition 
models in smoking cessation. A further challenge exists regarding the feasibility of developing DES 
models in smoking cessation, in terms of data availability and complexity of coding.  The purpose of 
our study was twofold: i) to explore the feasibility of developing a smoking cessation DES model; ii) 
to compare the results of a cohort-level state-transition and DES model in smoking cessation.  
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2. Methods 
2.1 Model settings  
We developed a cohort-level state-transition and a DES model to assess the cost-effectiveness of one 
intervention versus no treatment. The perspective of the analysis was the UK National Health Service 
(NHS) and Personal and Social Services (PSS), in accordance with the NICE reference case[18]. The 
discount rate for costs and benefits was 3.5% annually[18]. As far as possible, we kept all inputs the 
same between the models[18]. The intervention was a patch plus nasal spray, on which 27% of people 
had stopped smoking at 12 months[19] and the intervention cost £763.74[20] . No treatment was 
associated with a background net cessation rate of 2% annually, with no cost[17]. This net rate was 
also applied annually to people who had not quit on the intervention. The state-transition model used 
an annual cycle. Both models considered a lifetime horizon to incorporate the long-term health effects 
of smoking. We considered a cohort of people aged 16 years old, where 50% were male and 50% 
were female.   
2.2 Comorbidities 
Both models considered five smoking-related comorbidities: chronic obstructive pulmonary disease 
(COPD), coronary heart disease (CHD), myocardial infarction (MI), stroke and lung cancer. The 
utilities and costs associated with the comorbidities were based on those used in previous NICE 
smoking cessation models[11-17], updated with additional searches, are the same in the two models, 
and are shown in table 1. The state-transition model, like previous NICE smoking cessation 
models[21] uses prevalence data to model the proportion of the population with each comorbidity. In 
contrast, the DES considers patients developing a disease and so more naturally uses incidence data. 
This meant we could not use the same data as the state-transition model, and furthermore we could 
not obtain equivalent data from the same sources. Sources of incidence and prevalence data for each 
of the comorbidities are shown in Table 1. 
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2.3 Utility values 
Both models allowed utility to differ by smoker status and by presence of comorbidities. Vogl et al 
(2012) reported utilities for smokers and non-smokers by age, gender and smoker status [22]. The 
state-transition model assumed a constant utility for smokers (0.8486) calculated by subtracting the 
average disutility of light, moderate and heavy smokers from the utility for a never smoker, and a 
constant utility for former smokers (0.8669), calculated by subtracting the disutility of ex-occasional 
and ex-regular smokers from the utility for a never smoker. The state-transition model uses utility 
decrements for each comorbidity, calculated as the difference between the utility for the health state 
and the utility of the comorbidity in table 1. The DES uses the same source, and has the option to use 
the same data as the state-transition model or to vary utility by age and gender. In this scenario, the 
model applies utility data for moderate smokers for smokers and for ex-regular smokers for former 
smokers, and incorporates age by including an event for utility change which occurs when a person 
crosses an age band. Vogl et al (2012) provide utility decrements by number of comorbidities: 0.0938 
for one, 0.1811 for two, 0.2859 for three and 0.3354 for four or more [22]. The DES can count the 
number of comorbidities and use this data, or use the specific utility decrement for each comorbidity 
like the state-transition model. 
2.4 Model structures 
2.4.1 State-transition model 
In the state-transition model, a cohort of people transition between three health states: smoker, former 
smoker and dead. The prevalence of each comorbidity and the probability of death varied by smoker 
status. The model structure is shown in Figure 1. The population prevalence of each comorbidity and 
relative risk for a smoker versus a former smoker were taken from various sources ± the sources are 
shown in Table 1.  We combined the population prevalence, relative risk by smoker status, and 
proportion of smokers in the population to estimate age- and gender-specific prevalence by smoker 
status for each comorbidity, consistent with the approach taken in previous models[8, 21]. The 
equation below shows how prevalence in the general population can be decomposed, where C is 
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prevalence, P is the proportion within the population, RR is relative risk, general is general 
population, never is never smokers, former is former smokers and current is current smokers: ܥ௚௘௡௘௥௔௟ ൌ ܥ௡௘௩௘௥ ൈ  ௡ܲ௘௩௘௥ ൅  ܥ௡௘௩௘௥ ൈ ܴ ௙ܴ௢௥௠௘௥ǣ௡௘௩௘௥  ൈ ௙ܲ௢௥௠௘௥ ൅ ܥ௡௘௩௘௥ൈ ܴܴ௖௨௥௥௘௡௧ǣ௡௘௩௘௥  ൈ ௖ܲ௨௥௥௘௡௧ 
The equation can be rearranged to give the prevalence in the never smoker population, where the 
other components are known: 
ܥ௡௘௩௘௥ ൌ  ܥ௚௘௡௘௥௔௟௡ܲ௘௩௘௥ ൅  ௙ܲ௢௥௠௘௥ ൈ ܴ ௙ܴ௢௥௠௘௥ǣ௡௘௩௘௥ ൅ ௖ܲ௨௥௥௘௡௧ ൈ ܴܴ௖௨௥௥௘௡௧Ǣ௡௘௩௘௥ 
2.4.2 Discrete event simulation model 
The DES model simulates 5000 hypothetical people, whose individual pathway through the model is 
determined for each person. Whereas in a state-transition model a proportion of people have each 
event (or move to a different state) in each time cycle, in a DES each simulated person has each event 
at their own specific time. They then follow that sequence of events until they die and exit the model. 
7KHWLPHDWZKLFKHDFKHYHQWKDSSHQVGHSHQGVRQWKHSHUVRQ¶VFKDUDFWHULVWLFVKLVWRU\DQGUDQGRP
numbers. Comparing random numbers against probabilities of events occurring ensures that the 
appropriate proportion of patients have each event at each time point. 
The time to each comorbidity uses incidence data, which varies by smoker status. We used the same 
relative risks for smoker versus former smoker as the state-transition model, and incidence data from 
various sources (Table 2). Like the state-transition model, we combined the population incidence, 
relative risk by smoker status and proportion of smokers in the population to estimate incidence by 
smoker status for each comorbidity. 
The model structure is shown in Figure 2. A description of the process in the DES model is provided 
in the Supplementary Appendix.    
Research has shown that relative risks of developing comorbidities decreases with time since 
cessation, so the DES allows this[23]. The equation to model this has previously been used in 
smoking DES models[8] and considers age and gender in addition to time since cessation. Utilising 
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baseline characteristics and history is a known advantage of DES models over state-transition models 
and this equation was not considered in the state-transition model (although it may be possible with 
multiple tunnel states). To use the equation in the DES, we needed to adjust background disease 
incidence to consider the time at which the former smokers in the population had quit smoking. We 
estimated this using longitudinal data on the proportion of cigarette smokers who had quit by age and 
gender[24], combined with the proportion of smokers and non-smokers by age and gender[25], using 
the same approach to that used for estimating prevalence and incidence in the general population. In 
this case the relative risk for a former smoker is calculated as LQWKHHTXDWLRQEHORZZKHUHȖDQGȘDUH
comorbidity-specific parameters from Getsios et al[8] (we used the MI parameters as a proxy for 
CHD): 
 ? ൅ሺܴܴ௖௨௥௥௘௡௧ǣ௡௘௩௘௥ሻ  ൈ ݁൫ିఊൈ௘ሺషആൈȁೌ೒೐షఱబȁሻൈ௧௜௠௘௦௜௡௖௘௖௘௦௦௔௧௜௢௡൯ 
2.5 Mortality 
2.5.1 State-transition model 
Mortality varied by smoker status, using relative risk data from two studies by Doll[26, 27]. Mortality 
for former smokers was calculated by applying the relative risks for former and current smokers to the 
proportion of the UK population who are former and current smokers in a similar way to the equations 
for prevalence, and using lifetables from the Office for National Statistics (ONS). The relative risk for 
smokers was applied to the calculated former smoker mortality in the model. 
2.5.2 Discrete event simulation model 
Smoking cessation models which consider disease incidence may link comorbidity presence to 
mortality[28] rather than linking smoker status to mortality as the state-transition model does. The 
DES has the flexibility to either link comorbidity presence or smoker status to mortality, but not both. 
We calculated the relative risk of death for each comorbidity by combining comorbidity prevalence 
data (used in the state-transition model) with the number of all-cause deaths and number of deaths 
from each comorbidity from ONS death registration data[29], using the equation below: 
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ܴܴ௖௢௠௢௥௕௜ௗ௜௧௬ǣ௡௢௖௢௠௢௥௕௜ௗ௜௧௬ൌ  ݊ݑܾ݉݁ݎ݋݂݀݁ܽݐ݄ݏ݂ݎ݋݉ܿ݋݉݋ݎܾ݅݀݅ݐݕ݊ݑܾ݉݁ݎ݋݂݈݈ܽܿܽݑݏ݁݀݁ܽݐ݄ݏ ൊ ݌ݎ݁ݒ݈ܽ݁݊ܿ݁݋݂ܿ݋݉݋ݎܾ݅݀ݐݕ 
2.6 Long-term pathway 
The base case analysis considered only one smoking cessation attempt, but long-term effectiveness 
was explored in scenario analysis. The economic models for NICE guidelines consider only one 
smoking cessation attempt, and our primary aim was to understand whether using a DES in this 
scenario would lead to similar results. However, since the inclusion of multiple quit attempts has been 
highlighted as important[8], we considered a scenario in the DES whereby people who have quit 
smoking may later relapse. We used the annual long-term relapse probabilities considered in a 
previous UK economic evaluation of smoking cessation interventions: 0.129 for >1 to <5 years post 
FHVVDWLRQIRUWRC\HDUVSRVWFHVVDWLRQIRU!\HDUVSRVWFHVVDWLRQ [28]. 
2.7 Scenarios considered 
We ran the state-transition model for the described settings, and considered several scenarios in the 
DES, as follows: 
1. Mortality linked to smoker status, relative risk of comorbidities does not vary by time since 
cessation, utility data same as YHEC model. 
2. Same as Scenario 1, except mortality linked to comorbidity. As we believe this scenario is 
more realistic, we consider this as the basis for Scenarios 3-5.  
3. Same as Scenario 2, except relative risk of comorbidities varies by time since cessation. 
4. Same as Scenario 2, except vary utility by age and gender and using utility decrements for 
number of comorbidities. 
5. Same as Scenario 2, except considering long-term relapse. 
3. Results 
In both models and in all scenarios, the intervention was associated with higher costs, more life years 
and more quality-adjusted life years (QALYs) than the comparator. This is because the intervention 
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leads to fewer comorbidities and improves survival compared with no treatment, and so increases life 
years and QALYs. By reducing comorbidity occurrence, the intervention has some cost-offsets, so the 
incremental cost is less than the initial intervention cost. Results for all scenarios are shown in table 2. 
3.1 State-transition model 
In the state-transition model, the incremental costs are £540, and incremental QALYS are 0.16, 
leading to an incremental cost-effectiveness ratio (ICER) of £3,438/QALY. This is well below the 
£20,000 - £30,000/QALY range generally considered cost-effective by NICE[18]. It therefore appears 
that the intervention is good value for money. 
3.2 DES: Scenario 1 
In the DES, when mortality is linked to smoker status, the incremental costs are £47 and incremental 
QALYs are 0.12 yielding an ICER of £399/QALY. The total costs for intervention and comparator 
are much higher than in the state-transition model because people with costly comorbidities are not 
assumed to have any reduction in life expectancy, so accrue high costs.  
3.3 DES: Scenario 2  
The DES scenario linking mortality to comorbidities gives total and incremental results that are more 
comparable to the state-transition model. In this scenario, the people who develop comorbidities die 
sooner than the people who do not, and so do not incur such high costs. The number of people 
developing comorbidities does differ from the state-transition model, as might reasonably be expected 
for different data sources. A breakdown of comorbidity costs is shown in Table 3. 
3.4 DES: Scenario 3 
In the scenario where the relative risk of comorbidities varies by time since cessation, there are higher 
incremental QALYs and lower incremental costs, leading to a lower ICER than in Scenario 2. This is 
because the benefit of quitting smoking increases over time, and the smokers who quit do so at a 
young age in the model. The underlying incidence has changed in this scenario as we have adjusted 
the background incidence in the population to account for time since quitting in the background 
population. 
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3.5 DES: Scenario 4 
In the scenario where the number of, and not type of, comorbidity is linked to utility decrement, the 
total costs are unchanged and the QALYs increase in both arms. The incremental QALYs increase by 
0.03 and so the ICER decreases by £1,300 compared with Scenario 2. Accounting for the relative 
frequency of each comorbidity, the average comorbidity decrement in the base case is 0.20, which is 
higher than the decrement of 0.09 from Vogl et al (2012)[22]. When Vogl et al (2012) is used, the 
average utility increases, and so there are more QALYs gained from the incremental survival with the 
intervention. The effect is not large because the QALYs gained from former smokers generally having 
higher utility than smokers is unchanged. This scenario indicates that this change does not make a 
large difference to the results. 
3.6 DES: Scenario 5 
When long-term relapse is added in, the incremental costs remain relatively unchanged but the 
incremental QALYs decrease substantially, leading to a much higher ICER of £18,354. This is 
because the cost of the intervention remains the same, but the benefit is much reduced ± by 10 years 
almost 40% of the people who had quit have restarted smoking. This means that they only have a 
temporary benefit of abstaining for a short period of time.  
4. Discussion 
We found that the state-transition and DES models reported similar results, but that varying long-term 
assumptions in the DES dramatically changed the results. Whilst costs and QALYs were not sensitive 
to model structure or utility decrements, they were sensitive to the inclusion of a long-term relapse 
rate. This is despite using different underlying approaches and sources for modelling comorbidities.  
Leaviss et al (2014) noted that a DES would be needed to incorporate multiple quit attempts following 
relapse[28]. We note that the average number of quit attempts is 6-30, indicating how important it 
may be to incorporate more than one quit attempt, to accurately reflect reality[30]. That said, if the 
sequence of subsequent treatments is identical between intervention and comparator, then a model 
may only need to capture the time period between the first quit attempt and relapse. However, the 
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probability of successfully quitting on later treatments may depend on factors such as age, number of 
and time since previous quit attempts[31], which may then vary between the arms.  
To our knowledge, we are the first to directly compare state-transition and DES structures in smoking 
cessation.  Claxton et al (2014)[32] compared a patient level simulation model with a cohort state-
transition model in ophthalmology and found that the difference in results was relatively small using a 
simple patient level simulation, but much greater using more sophisticated patient level simulations. 
Claxton et al (2014) [32]noted that patient level simulations are better able to accurately represent the 
real-world in ophthalmology. Simpson et al (2009) [33] compared a DES with a state-transition model 
in HIV and found that the results were similar but not identical, and that the DES had better long-term 
predictive validity. Stevenson et al (2016)[34] reviewed six economic models developed by 
manufacturers of biologics in rheumatoid arthritis, where three used DES, two used cohort-level state-
transition models and one used an individual patient simulation model with fixed cycle lengths. The 
six models used similar data and assumptions and reported broadly similar results. In an independent 
analysis using a DES, Stevenson et al (2016) [34] found that long-term assumptions about disease 
progression had a large influence on the cost-effectiveness results.   
 
The DICE framework can be used to build state-transition or DES models, so in future researchers 
could compare multiple model structures within one Microsoft Excel workbook. We show that where 
long-term treatment effectiveness and the downstream pathway does not vary between treatments, 
state-transition and DES models give comparable results and may be considered equally valid. State-
transition models can make use of ULFKGDWDVRXUFHVVXFKDV'ROO¶VVWXG\UHSRUting mortality by 
smoker status. On the other hand, a DES model would give the same results as a state-transition 
model for one line of treatment, so the structure is not expected to introduce bias when used for 
multiple lines or sequences of treatments.  
We have demonstrated the feasibility of building a DES using readily available data, mostly using 
inputs that would be identified for a standard state-transition model. The DES did however require 
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additional data sources for calculating inputs, such as for time since cessation and mortality risk by 
comorbidity. This increased the workload associated with developing the model, and increased the 
parameter uncertainty as more data sources were used ± although we did strive to use recent, large, 
national datasets as far as available. The additional flexibility of the DES framework means that it 
could now be updated as data becomes available or as the decision problem develops, whereas 
adapting state-transition models to include additional health states or patient characteristics can be 
time consuming[5]. The flexibility of the DES means that it can use consistent data sources where 
available ± for example in using utility data from Vogl to consider the impact of smoker status and 
comorbidity from one dataset rather than combining from multiple sources which may not necessarily 
be valid.  
The main limitations of our current analysis lie within the data inputs used in the DES. Firstly, 
although the DES can link mortality to either smoker status or to comorbidity prevalence, neither 
approach is perfect. When mortality was linked to smoker status (in Scenario 1), people with 
comorbidities did not have any reduction in life expectancy and so incurred high costs. In the state-
transition model which links mortality to smoking status, using population prevalence adjusts for this 
by considering a relatively lower proportion of people with comorbidities in advanced age. Using 
incidence in the DES model does not do this, suggesting that the results and approach in this scenario 
may not be valid. Linking mortality to comorbidities may be more appropriate, but we considered 
only five comorbidities, and it is possible that other comorbidities may also impact on mortality, for 
example through wound complications[35, 36].  It is possible that, individually, each additional 
comorbidity would have too small an impact on mortality to have been demonstrated in the literature 
but, cumulatively, the impact of several different comorbidities could have a meaningful clinical 
effect.  By linking smoking status itself with mortality, this would be captured, whereas explicitly 
linking mortality to five comorbidities could underestimate the true effect. Secondly, the use of 
empirical frequencies for incidence and death mean that the model can only sample the time to event 
to the nearest year, and looking up event probabilities from a table increases the model run time 
compared with sampling from a probability distribution. Thirdly, that the information on long-term 
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relapse and intervention effectiveness are from separate studies and do not necessarily consider 
identical patient populations. Despite this, we consider that our analyses provide a pragmatic 
comparison of two model structures. Our analysis indicates that smoking cessations may be less likely 
to be cost-effective when a longer pathway is modelled. Previously, most economic evaluations using 
one year quit rates as a proxy for long-term cessation have found individual smoking cessation 
interventions to be cost-effective [11-14, 37, 15-17, 28]. This is unsurprising when we consider the 
substantial health benefits and cost-offsets gained by each individual quitter. However, if we were 
evaluating the addition of one intervention, with long-term relapse, to a pathway of treatments, then 
this may not be true. Therefore, it is important that the economic model captures the relevant pathway, 
and that the positioning of a new intervention within the pathway is understood. 
5. Conclusion 
We have found that model structures themselves do not influence smoking cessation cost-
effectiveness results, but that long-term assumptions do. Before building an economic model, 
developers should first consider the full treatment pathway in the decision problem. They should then 
develop a model to incorporate the long-term differences between treatment and comparator. The 
choice of model structure is only important inasmuch as it allows all relevant outcomes to be 
incorporated. When there is variation in long-term predictions, economic models need a structure that 
can reflect this.  
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Figure captions and legends 
Figure 1: State-transition model structure 
CHD: coronary heart disease, COPD: chronic obstructive pulmonary disease, MI: myocardial 
infarction 
 
Figure 2: DES model structure 
 
CHD: coronary heart disease, COPD: chronic obstructive pulmonary disease, MI: myocardial 
infarction
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Table 1: Comorbidity data 
Comorbidity Cost Cost source* Utility 
value  
Utility value source Relative risk 
data source 
Prevalence data 
source 
Incidence data 
source 
Stroke £5,504 
NICE CG92 Full 
guideline[38] 
0.48 
Tengs and Wallace[39]  
Myint et al. 
(2008) [40] 
Bhatnagar et al. 
(2015)[41]  
British Heart 
Foundation 
(2009) [42]  
Lung cancer £9,254 
Cancer Research 
UK[43]  
0.61 
Bolin et al. (2009) [10] 
Pesch et al. 
(2012) [44] 
Maddams et al. 
(2009) [45] 
Office for 
National 
Statistics (2014) 
[46] 
MI £1,012 Godfrey et al[47].  0.80 
Tengs and Wallace  
[39] 
Prescott et al. 
(1998) [48] 
Bhatnagar et al. 
(2015) [41] 
British Heart 
Foundation 
(2012) [49] 
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CHD £1,323 
British Heart 
Foundation. 
Cardiovascular 
Disease Statistics[50]  
0.80 
Stevanovic[51] 
Shields et al. 
(2013) Shields, 
2013 #8} 
Liu et al. (2002) 
[52]. Assumed 
that 12 to 15 
year olds had 
0% prevalence.   
British Heart 
Foundation 
(2012) [49] 
COPD £546 
NICE CG101[53] 
 
0.73 
Rutten-van Molken et 
al.  2006 [54] 
Lokke et al. 
(2006) [55] 
Public Health 
England data 
set. Assumed 12 
to 15 year olds 
had 0.1% 
prevalence.  
(1.28%) [56] 
British Lung 
Foundation 
(2016) [57] 
*All costs inflated to 2014/15 using PSSRU[58] 
CHD: coronary heart disease, COPD: chronic obstructive pulmonary disease, MI: myocardial infarction, NICE: National Institute for Health and Care 
Excellence
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Table 2: Cost-effectiveness results 
Scenario Intervention Total Cost Total QALYs Incremental Cost Incremental 
QALYs 
ICER 
State-
transition 
Patch + spray £4,809  21.83       
No treatment £4,270 21.67 £540 0.16 £3,438 
DES Scenario 
1 
Patch + spray £9,530 19.67       
No treatment £9,484 19.55 £47 0.12 £399 
DES Scenario 
2  
Patch + spray £4,213 19.94       
No treatment £3,595 19.83 £618 0.11 £5,577 
DES Scenario 
3 
 
Patch + spray £4,392 19.93       
No treatment £3,948 19.75 £444 0.18 £2,467 
DES Scenario 
4 
 
Patch + spray £4,213 20.26       
No treatment £3,595 20.12 £618 0.14 £4,266 
Patch + spray £3,941 19.85       
23 
 
DES Scenario 
5 No treatment £3,317 19.81 £623 0.03 £18,354 
 
CHD: coronary heart disease, COPD: chronic obstructive pulmonary disease, DES: discrete event simulation, ICER: incremental cost-effectiveness ratio, 
MI: myocardial infarction, QALY: quality adjusted life year
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Table 3: Cost breakdown 
Cost 
element 
Intervention costs Comparator costs 
State- 
transition 
Scenari
o 1 
Scenari
o 2 
Scenari
o 3 
Scenari
o 4 
Scenari
o 5 
State- 
transition 
Scenari
o 1 
Scenari
o 2 
Scenari
o 3 
Scenari
o 4 
Scenari
o 5 
Stroke Cost £1,746 £805 £883 £943 £883 £309 £1,817 £613 £671 £721 £671 £308 
Lung cancer 
Cost £268 
£7,195 £1,760 £1,867 £1,760 £2,054 
£296 
£8,040 £2,053 £2,302 £2,053 £2,174 
MI Cost £240 £45 £51 £53 £51 £52 £250 £47 £53 £55 £53 £52 
CHD Cost £1,157 £221 £235 £199 £235 £190 £1,182 £215 £227 £206 £227 £192 
COPD Cost £634 £500 £520 £565 £520 £572 £725 £569 £590 £664 £590 £592 
Intervention 
cost £764 
£764 £764 £764 £764 £764 
£0 
£0 £0 £0 £0 £0 
Total cost £4,809 
£9,530 £4,213 £4,392 £4,213 £3,941 
£4,270 
£9,484 £3,595 £3,948 £3,595 
£3,317   
  
CHD: coronary heart disease, COPD: chronic obstructive pulmonary disease, DES: discrete event simulation, ICER: incremental cost-effectiveness ratio, 
MI: myocardial infarction, QALY: quality adjusted life year
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Supplementary appendix: description of DES 
Each person is assigned a sex and age according to baseline distributions. Their smoker status is 
LQLWLDOO\VHWWRVPRNHU$XWLOLW\YDOXHLVDVVLJQHGGHSHQGLQJRQWKHSHUVRQ¶VVH[DQGVPRNHUVWDWXV
(and age, depending on selected settings). The time to each of the comorbidities and death is 
randomly sampled from its distribution. The time to utility change depends on the age of the person, 
or may be infinite if utility is not chosen to vary by age. The person then moves immediately into a 
Quit Attempt, where a treatment (intervention or comparator) is assigned.  
In the Quit Attempt, a random number is compared with the probability of successfully quitting on 
that treatment. If the random number is less than or equal to that probability, then the time to the event 
Success is set to the duration of the treatment and the time to the event Failure is set to be infinite.  If 
the random number is greater than that probability, then the time to the event Failure is set to the 
duration of the treatment and the time to the event Success is set to be infinite.  
There is then Dµ'HOD\¶EHIRUHWKHQH[WHYHQW± which may be Failure, Success, Utility Change (if 
LQFOXGHGDQ\RIWKH&RPRUELGLWLHVRU'HDWKGHSHQGLQJRQZKLFKKDVWKHVKRUWHVWWLPH7KLVµ'HOD\¶
happens between any two events, and during this period the person accrues QALYs and costs.  
In the Failure event, the person is still a smoker so their smoker status does not change, nor does their 
utility value nor time to any subsequent events. The time to next Quit Attempt is sampled, since the 
person may attempt to quit smoking again.  
In the Success event, the person has now become a non-smoker, so their smoker status changes to be a 
non-smoker. Since utility value and time to Comorbidities (and Death, depending upon settings) vary 
by smoker status, these are then updated. Where long-term relapse is included, the time to Relapse 
after Success is sampled.  
In the Relapse event, the person becomes a smoker again, so their smoker status, utility value and 
time to Comorbidities (and Death, depending upon settings) are updated. The time to next Quit 
Attempt is sampled. 
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,QWKH8WLOLW\&KDQJHHYHQWLILQFOXGHGWKHSHUVRQ¶VXWLOLW\YDOXHFKDQJHVEHFDXVHWKH\KDYHFURVVHG
an age band. The time to next Utility Change is calculated. 
In each of the Comorbidity events (MI, CHD, StrokH&23'DQG/XQJ&DQFHUWKHSHUVRQ¶VVWDWXV
for that comorbidity is updated. Their utility value therefore changes, and they incur annual costs 
associated with that comorbidity. Since each person can only have each comorbidity once, the time to 
that Comorbidity is then set to be infinite. In the scenarios where comorbidities are associated with 
increased mortality, the time to death is resampled. 
In the Death event, the time to End is set to be the current die, the person dies and exits the model.  
In the End event, all results are reported.  
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